Problem

Novelcare addresses the clinical-trial industry’s central operational bottleneck: recruiting enough eligible patients. Around 80% of trials miss their initial enrollment target or timeline, creating costly delays and lost revenue for sponsors. The problem is especially acute for community practices: doctors struggle to track which nearby studies are relevant to which patients, while trial criteria can contain more than 30 inclusion and exclusion conditions that are difficult to evaluate manually.

The killer use case is turning an ordinary community practice into a source of trial referrals. Novelcare identifies medically relevant studies for patients already in a doctor’s panel, helping patients who need alternatives to existing treatment, cannot afford standard care, or want access to new therapies while giving sponsors a more direct path to eligible participants.

Product / Service

Novelcare is a HIPAA-compliant clinical-trial matching platform built around electronic medical-record data. Its technology scans for nearby studies, compares their criteria with patient records through secure EMR integrations, and places potential matches in a provider inbox as readable Match Reports. The doctor reviews the match and can notify the patient with a click; Novelcare then handles the subsequent connection. Its Bulk FHIR architecture indexes records in a matching engine, which supports the varied EHR systems used by small and midsize independent practices.

The model is designed to reduce friction for every participant. Trial treatments are free, and studies typically reimburse patients for time and travel. Community practices with fewer than one million patients can use Novelcare for free, while larger practices pay $100 per provider per month; Novelcare can also pay up to $200 for certain chart reviews. For trial sites, the service offers local physician referrals and charges only for randomizations, or is free when a sponsor invites the site.

Market

Novelcare competes in B2B healthcare IT at the intersection of clinical-trial patient matching, provider activation, and trial recruitment. Comparable offerings include Tempus TIME, which uses an AI-enabled trial network to help providers match patients and accelerate enrollment, and TrialX, whose platform matches patients to trials using EHR data. Antidote is another adjacent competitor in digital clinical-trial search and point-of-care recruitment. Novelcare’s differentiation is its focus on community practices and its two-sided workflow connecting those practices and their patient panels to trial sites.

The company appears commercially active but early. Y Combinator identifies Novelcare as a Winter 2023, active healthcare enterprise-software company founded in 2022, and an interoperability case study reports integrations with nine EHRs, with most users being small to midsize independent outpatient practices. Its live pricing, provider sign-up flow, and trial-site referral model show a monetizable product, but the available evidence does not disclose customer counts, match volume, patient enrollments, randomizations, or realized revenue. It is therefore better characterized as an early commercial-stage company with traction signals than definitively as either scaled or pre-revenue.